Weekly Investment Analysts’ Ratings Changes for Keros Therapeutics (KROS)

Keros Therapeutics (NASDAQ: KROS) recently received a number of ratings updates from brokerages and research firms:

• 8/8/2026 – Keros Therapeutics was upgraded by Wall Street Zen from “strong sell” to “sell”.
• 8/4/2026 – Keros Therapeutics had its price target lowered by Wells Fargo & Company from $20.00 to $18.00. They now have an “overweight” rating on the stock.
• 8/4/2026 – Keros Therapeutics had its “buy” rating reaffirmed by HC Wainwright. They now have a $20.00 price target on the stock.
• 8/4/2026 – Keros Therapeutics had its price target lowered by Leerink Partners from $30.00 to $23.00. They now have an “outperform” rating on the stock.
• 7/29/2026 – Keros Therapeutics was downgraded by Zacks Research from “hold” to “strong sell”.

Insider Transactions at Keros Therapeutics

In other news, Director Alpna Seth sold 2,625 shares of the stock in a transaction that occurred on Thursday, June 4th. The shares were sold at an average price of $10.72, for a total value of $28,140.00. Following the completion of the transaction, the director directly owned 9,767 shares in the company, valued at $104,702.24. This trade represents a 21.18% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is accessible through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, Director Julius Knowles sold 2,625 shares of the firm’s stock in a transaction that occurred on Thursday, June 4th. The shares were sold at an average price of $10.73, for a total transaction of $28,166.25. Following the transaction, the director owned 10,958 shares in the company, valued at $117,579.34. This represents a 19.33% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. In the last three months, insiders sold 8,425 shares of company stock valued at $89,994. Company insiders own 12.60% of the company’s stock.

Keros Therapeutics, Inc (NASDAQ: KROS) is a clinical-stage biopharmaceutical company dedicated to discovering and developing novel therapies for disorders of erythropoiesis and iron regulation. The company’s research centers on modulating the transforming growth factor-beta (TGF-β) superfamily to rebalance hematopoiesis and improve red blood cell production. By targeting key signaling pathways involved in anemia, Keros aims to provide new treatment options for patients with myelodysplastic syndromes, beta-thalassemia and other chronic anemias with significant unmet need.

The company’s lead product candidate, KER-050, is an engineered activin receptor ligand trap designed to restore effective erythropoiesis and reduce transfusion dependence in patients with anemia associated with myelodysplastic syndromes and primary myelofibrosis.